Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07654972
Recruiting Phase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07654972 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Phase 1
Started
2026-06-24
Last updated
2026-10-15

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

LY4174794LY4174794Placebo

LY4174794: Administered SC.

LY4174794: Administered IV.

Placebo: Administered SC.

Study summary

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 30 to 39 weeks (7 to 10 months).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-reported stable weight for 3 months prior to screening Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data * Is an individual of childbearing potential (IOCBP)

Primary outcome measure(s)

  • Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline through end of the Follow-up (Week 25)
    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
  • Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration — Baseline through end of the Follow-up (Week 33)
    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.

Trial sites (3)

FacilityCityRegionStatus
ICON Early Phase Services, LLC San Antonio Texas Recruiting
ICON Early Phase Services, LLC Salt Lake City Utah Not Yet Recruiting
Lilly Centre for Clinical Pharmacology Singapore Singapore Not Yet Recruiting

More Eli Lilly and Company trials in the USA

A Study of LY4178256 in Healthy Participants Recruiting
A Study of LY3971297 in Participants With Heart Failure Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Active, not recruiting

Other trials for the same condition

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) Recruiting
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Starting soon
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07654972 on ClinicalTrials.gov ↗ ← All trials in the USA